首页> 外文期刊>Clinical neuropharmacology >Orofacial dyskinesia after moxifloxacin treatment-a case with normal hepatorenal function and review of literature
【24h】

Orofacial dyskinesia after moxifloxacin treatment-a case with normal hepatorenal function and review of literature

机译:莫西沙星治疗后口面运动障碍-肝肾功能正常的病例及文献复习

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Orofacial dyskinesia is rarely reported with antibiotics. Among antibiotics, third-generation fluoroquinolones are known to cause movement disorders. We report the first patient who developed orofacial dyskinesia after taking a fourth-generation fluoroquinolone, namely, moxifloxacin. METHODS: The patient is a 58-year-old woman who was treated with moxifloxacin for acute bronchitis. She developed orofacial dyskinesia involving the tongue, lips, and facial muscles after treatment. RESULTS: Discontinuation of moxifloxacin and treatment with clonidine resulted in significant reduction of orofacial dyskinesia over the period of 8 to 12 weeks. A review of literature shows reports of a variety of involuntary movements with third-generation fluoroquinolones, mostly manifesting in patients with impaired renal and kidney function. CONCLUSIONS: The fourth-generation fluoroquinolone moxifloxacin can cause orofacial dyskinesia like third-generation fluoroquinolone antibiotics and in a patient with normal renal and liver function.
机译:背景:很少有抗生素引起口面部运动障碍。在抗生素中,已知第三代氟喹诺酮类会引起运动障碍。我们报告了第一例服用第四代氟喹诺酮(莫西沙星)后发生口面运动障碍的患者。方法:该患者是一名58岁的女性,接受莫西沙星治疗急性支气管炎。治疗后,她出现了口舌运动障碍,累及舌头,嘴唇和面部肌肉。结果:莫西沙星的停用和可乐定的治疗可在8到12周的时间内显着减少口面部运动障碍。文献综述显示,第三代氟喹诺酮类药物会发生多种非自愿运动,主要表现在肾功能和肾脏功能受损的患者中。结论:第四代氟喹诺酮莫西沙星可引起口面部运动障碍,如第三代氟喹诺酮抗生素,且肾和肝功能正常。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号